An official website of the United States government
September 29, 2026 Edition
News
Antiviral drug did not improve Long COVID symptoms
A clinical trial for Long COVID found that treating patients with a common antiviral drug for up to 25 days did not improve symptoms.
News
tRNA treatment may help restore cystic fibrosis proteins
Lipid nanoparticles delivering engineered transfer RNA restored functional proteins in cell and animal models of cystic fibrosis.
News
Bacterial infection may alter developing gut
C. difficile bacteria caused lasting changes to cells in the intestines of newborn mice.
Displaying 631 - 637 of 912
Cancer drug may reduce symptoms of severe COVID-19
In patients with COVID-19, off-label use of a cancer drug reduced respiratory distress and over-reactive immune responses. The results were used to inform the design of a clinical trial.
Largest catalog of human genetic diversity
Using DNA from over 140,000 people, researchers created a massive catalog of human genome data, along with tools to understand it.
Researchers create developmental map of mouse cochlea
Scientists mapped how sensory cells develop in the mouse cochlea, a key sound-sensing structure in the inner ear. The findings could help lead to therapies for some forms of hearing loss.
Blood proteins associated with persistent symptoms after brain injury
After mild traumatic brain injury, military veterans with higher blood levels of a protein released by injured neurons were more likely to report long-term symptoms.
Beneficial bacteria prevent recurring bacterial vaginosis
An experimental treatment for a common infection called bacterial vaginosis significantly reduced the rates of recurrence.
Scientists find new pain-suppression center in the brain
Scientists identified a group of neurons in mice that blunt pain within the brain. Such neurons could be promising targets for new non-addictive therapies for chronic pain.
Early results show benefit of remdesivir for COVID-19
Early clinical trial results support the use of remdesivir for patients with severe COVID-19 who require supplemental oxygen, but more research is needed to improve outcomes for people with COVID-19.